2024-04-09T15:28:30-05:00 2023-12-31 760269860 Blazek & Vetterling 2900 Weslayan Suite 200 Houston TX 77027 990 2023-01-01 880517430 CLL Global Research Foundation c/o William Wierda CLLG 7137452376 1515 Holcombe Blvd Unit 428 Houston TX 77030 Dr William Wierda President & CEO 7137452376 2024-04-09 1 Dr William Wierda 999009999 0 Barbara Murphy P01386215 7134395739 2024-04-09 3 AAL1 IAL1 2023 2023-04-26 12:10:37Z Dr William Wierda 1515 Holcombe Blvd Unit 428 Houston TX 77030 24880681 0 X www.cllglobal.org X 2003 TX To accelerate progress toward the control and cure of chronic lymphocytic leukemia (CLL). 11 10 0 10 0 0 2693348 2469879 0 0 -973897 65730 0 0 1719451 2535609 1903748 2832011 0 0 70000 80000 0 0 42858 162976 217578 2136724 3129589 -417273 -593980 10938772 12019246 2088716 2876858 8850056 9142388 X CLL Global's mission is to abolish chronic lymphocytic leukemia (CLL) as a threat to the life and health of patients by accelerating CLL research. 0 0 2832011 2832011 RESEARCH GRANTS: The CLL Global Research Foundation's primary activity is to accelerate research. The need is urgent to accelerate promising, untapped areas of research. CLL Global provides grants through several mechanisms to fund novel, patient-oriented concepts. The intention is to fund the best CLL science in the world. In particular, CLL Global targets monoclonal antibodies, prognostic factors, vaccines & gene therapy, CLL survival pathway, genetics, molecular targets, and drug development. Continued on Schedule O A Scientific Advisory Board (SAB) develops the research priorities and oversees the development and implementation of the submission, evaluation and funding process for grant application cycles. SAB members have extensive experience in treating CLL patients, developing new drugs and other tools, and studying various aspects of the disease. The research grant section also allows support of postdoctoral fellows conducting a CLL-specific project. In 2023, CLL Global awarded new research/individual grants ranging from $100,000-$250,000. Applicants initially submit proposals for up to $110,000 in funding for one year. Applicants identify project milestones. Upon demonstration of sufficient progress, investigators will be considered for a second year of funding. For accounting purposes, CLL Global expenses grants at the time of completion of a sponsored research agreement. 146498 ALLIANCE: The US/European Alliance for the Therapy of CLL (Alliance) is comprised of 25 individuals from the United States and Europe, representing the world's experts in CLL research. The members are divided into working groups focusing on one of five big ideas in CLL research (new drugs, gene/vaccine therapy, genetics, CLL-stromal interactions, transplant/immune reconstitution). The Alliance was built to encourage close collaboration within and among working groups. As such, meetings are held to bring investigators together to collaborate. 25184 EDUCATION: CLL Global Research Foundation hosts annual interactive patient education events where CLL patients learn about emerging therapies, current treatment options and support resources from leading CLL experts. Both virtual and in-person events were held in 2023. 3003693 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 7 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 11 10 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 X William Wierda 7137452376 1515 Holcombe Unit 428 Houston TX 77030 X Michael J Keating Founding Director 2.00 X X 0 0 0 William Wierda President & CEO 4.00 X X 14531 0 0 Phyllis Cohen Director 1.00 X 0 0 0 Richard Evans Director 1.00 X 0 0 0 Louis Katopodis Director 1.00 X 0 0 0 Diane Lee Kraitman Director 1.00 X 0 0 0 Richard Marschner Director 1.00 X 0 0 0 Robert Nichols Director 1.00 X 0 0 0 William Plunkett Director 1.00 X 0 0 0 Martin Raber Director 1.00 X 0 0 0 Steve Winfield Director 1.00 X 0 0 0 Sam Margaret Pace CDO 35.00 X 145850 0 0 160381 0 0 1 0 0 1 0 2469879 2469879 296996 296996 22113806 22345072 -231266 -231266 -231266 2535609 0 0 65730 2732011 2732011 100000 100000 60000 38400 10800 10800 20000 17600 1200 1200 19532 19532 13149 13149 7255 7255 15701 733 10131 4837 39493 13239 7488 18766 56006 56006 63426 45704 17722 3016 3016 3129589 3003693 83038 42858 1699949 2540044 1719119 399559 659721 504594 1700 4500 6858283 8570549 10938772 12019246 20786 34852 2067930 2842006 2088716 2876858 X 8190335 8637794 659721 504594 8850056 9142388 10938772 12019246 -593980 886312 0 X 0 1 X 1 0 X 1774190 2082621 2155908 2693348 2469879 11175946 95276 97839 97840 98489 100381 489825 1869466 2180460 2253748 2791837 2570260 11665771 8036931 3628840 150924 168679 226764 131862 296996 975225 12640996 0.28710 0.31380 X Based on the information set forth below, CLL Global Research Foundation believes it qualifies as a publicly supported charity described in IRC 509(a)(1) pursuant to the facts and circumstances test found in Treasury Regulation 1.170A-9(e)(3). Percentage of Financial Support: CLL Global Research Foundation's public support percentage stands at 28.71% for the 2023 calendar year.Active Fundraising Efforts: The organization's ongoing research grants have been made possible by large donations from a significant donor. Over the last few years, this donor has increased their annual support of the Foundation. CLL Global Research Foundation has conducted a continuous and bona fide fundraising program designed to attract new and additional public and governmental support. In the past two years, CLL Global Research Foundation has invested more staff and financial resources in its development program in order to expand and diversify its funding base. Representative Governing Body: CLL Global Research Foundation's board of directors is comprised of 11 members representing expertise in medical research and community enterprises, all of whom are passionate about funding CLL research and treatment options. Sources of Support: CLL Global Research Foundation receives grants from an ever-expanding donor base including individuals, foundations, companies and governmental agencies. The Foundation is currently making improvements to its development strategy in order to attract new and additional public support. Program Availability and General Public Participation: CLL Global Research Foundation seeks to make grants to various medical institutions who are at the forefront of conducting CLL research, both in the United States and worldwide. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 3509153 886312 100381 986693 2522460 13149 13149 2535609 3216821 100381 100381 3116440 13149 13149 3129589 1 Middle East and North Africa 0 0 Grantmaking 100000 0 0 0 0 0 0 100000 0 100000 Middle East and North Africa CLL research 100000 EFT 0 1 0 0 0 0 0 0 Part I, Line 2: After a grant is awarded, members of the Scientific Advisory Board (SAB) review annual progress reports to determine whether an additional year of funding is warranted. If additional funds are awarded, grant recipients must provide additional progress reports to the SAB. Part I, line 3: Part I, column (f) amounts are reported on the accrual method of accounting. 1 UT MD Anderson Cancer Center PO Box 4486 Houston TX 77210 746001118 Govt. 2267011 0 CLL research grant Feinstein Institute for Medical Research 972 Brush Hollow Rd 5th Fl Westbury NY 11590 112673595 501(c)(3) 115000 0 CLL research grant Ohio State University 281 W Lane Ave Columbus OH 43210 316025986 Govt. 350000 0 CLL research grant 3 Part I, Line 2: After a grant is awarded, members of the Scientific Advisory Board (SAB) review a progress report and determine whether a second year of funding is warranted. If additional funds are awarded, grant recipients must provide additional progress reports. 0 0 0 0 0 0 0 0 0 Sam Margaret Pace CDO 145850 0 0 0 0 0 0 0 0 0 145850 0 0 0 William Wierda President & CEO 14531 0 0 0 0 0 0 0 0 0 14531 0 0 0 Compensation from Unrelated Organization Dr. William Wierda and Sam (Margaret) Pace are employed by The University of Texas MD Anderson Cancer Center, who determines the amount of their compensation. MD Anderson donates the time to allow them to perform their assigned functions for CLL Global Research Foundation. The amounts paid by MD Anderson attributable to work for the Foundation are reported in column D of Part VII, and Schedule J, Part II. Mark Keating Officer's son 21022 IT services 0 Form 990, Part VI, Section B, line 11b A draft of Form 990 is sent to the board of directors in advance of the April/May board meeting. The board reviews Form 990 prior to and during the meeting. A formal motion is considered to approve and submit Form 990 to the IRS. Form 990, Part VI, Section B, line 12c Each board member is required to make an annual disclosure of any conflicts of interest. A board meeting is then held to review any disclosed conflicts. Form 990, Part VI, Section B, line 15a The top officials are employed and compensated by the University of Texas MD Anderson Cancer Center. See Schedule J and Schedule O. Form 990, Part VI, Section C, line 19 These documents are provided upon request. Part VII Compensation Explanation - William Wierda Dr. William Wierda is employed by the University of Texas MD Anderson Cancer Center. MD Anderson allows him time as needed to perform his assigned functions for CLL Global. In 2023, an estimated amount of $14,531 of the compensation he received from MD Anderson is attributed to his services performed for CLL Global. MD Anderson donates the cost of providing these services to CLL Global. This amount has been reported on Part VII, column (d). Part VII Compensation Explanation - Sam (Margaret) Pace Sam (Margaret) Pace is employed by the University of Texas MD Anderson Cancer Center. MD Anderson allows her time as needed to perform her assigned functions for CLL Global. In 2023, an estimated amount of $85,850 of the compensation she received from MD Anderson is attributed to her services performed for CLL Global. MD Anderson donates the cost of providing these services to CLL Global. This amount has been reported on Part VII, column (d), in addition to $60,000 of compensation paid directly by CLL Global.